Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.

Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T.

Mol Cancer Ther. 2008 May;7(5):1176-84. doi: 10.1158/1535-7163.MCT-07-2215.

PMID:
18483305
[PubMed - indexed for MEDLINE]
Free Article
2.

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.

Pardanani A.

Leukemia. 2008 Jan;22(1):23-30. Epub 2007 Sep 20. Review.

PMID:
17882282
[PubMed - indexed for MEDLINE]
3.

JAK2 kinase inhibitors and myeloproliferative disorders.

Chen AT, Prchal JT.

Curr Opin Hematol. 2010 Mar;17(2):110-6. doi: 10.1097/MOH.0b013e3283366b91. Review.

PMID:
20087176
[PubMed - indexed for MEDLINE]
4.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
[PubMed - indexed for MEDLINE]
Free Article
5.

Therapeutic potential of JAK2 inhibitors.

Verstovsek S.

Hematology Am Soc Hematol Educ Program. 2009:636-42. doi: 10.1182/asheducation-2009.1.636. Review.

PMID:
20008249
[PubMed - indexed for MEDLINE]
Free Article
6.

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.

Panani AD.

Cancer Lett. 2009 Oct 18;284(1):7-14. doi: 10.1016/j.canlet.2009.02.010. Epub 2009 Mar 9. Review.

PMID:
19269737
[PubMed - indexed for MEDLINE]
7.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
[PubMed - indexed for MEDLINE]
8.

Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.

Wadleigh M, Tefferi A.

Clin Adv Hematol Oncol. 2010 Aug;8(8):557-63. Review.

PMID:
20966892
[PubMed - indexed for MEDLINE]
9.

The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases.

Hitoshi Y, Lin N, Payan DG, Markovtsov V.

Int J Hematol. 2010 Mar;91(2):189-200. doi: 10.1007/s12185-010-0531-y. Epub 2010 Feb 27. Review. Erratum in: Int J Hematol. 2010 Apr;91(3):555.

PMID:
20191331
[PubMed - indexed for MEDLINE]
10.

Janus kinase 2 inhibitors in myeloproliferative disorders.

Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4. Review.

PMID:
21128825
[PubMed - indexed for MEDLINE]
11.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Bhagwat N, Levine RL, Koppikar P.

Int J Hematol. 2013 Jun;97(6):695-702. doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14. Review.

PMID:
23670175
[PubMed - indexed for MEDLINE]
12.

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.

Tefferi A, Gilliland DG.

Mayo Clin Proc. 2005 Jul;80(7):947-58. Review.

PMID:
16007902
[PubMed - indexed for MEDLINE]
13.

Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Santos FP, Verstovsek S.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1083-99. doi: 10.1016/j.hoc.2012.07.008. Epub 2012 Aug 21. Review.

PMID:
23009939
[PubMed - indexed for MEDLINE]
14.

Hemopoiesis in Ph-negative chronic myeloproliferative disorders.

Spanoudakis E, Tsatalas C.

Curr Stem Cell Res Ther. 2009 May;4(2):154-60. Review.

PMID:
19442200
[PubMed - indexed for MEDLINE]
15.

Breakthroughs in myeloproliferative neoplasms.

Santos FP, Verstovsek S.

Hematology. 2012 Apr;17 Suppl 1:S55-8. doi: 10.1179/102453312X13336169155574. Review.

PMID:
22507780
[PubMed - indexed for MEDLINE]
16.

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Gnanasambandan K, Sayeski PP.

Curr Med Chem. 2011;18(30):4659-73. Review.

PMID:
21864276
[PubMed - indexed for MEDLINE]
17.

The many faces of Janus kinase.

Seavey MM, Dobrzanski P.

Biochem Pharmacol. 2012 May 1;83(9):1136-45. doi: 10.1016/j.bcp.2011.12.024. Epub 2011 Dec 24. Review.

PMID:
22209716
[PubMed - indexed for MEDLINE]
18.

Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.

Mesa RA.

Hematology Am Soc Hematol Educ Program. 2007:355-62. Review.

PMID:
18024651
[PubMed - indexed for MEDLINE]
Free Article
19.

Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.

Godeny MD, Sayeski PP.

Anticancer Agents Med Chem. 2007 Nov;7(6):643-50. Review.

PMID:
18045059
[PubMed - indexed for MEDLINE]
20.

The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.

Baskin R, Majumder A, Sayeski PP.

Curr Med Chem. 2010;17(36):4551-8. Review.

PMID:
21062251
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk